Liquid Biopsy in Glioblastoma Treated With Chemoradiation and an Oxygen Therapeutic

NCT07417774 · tracked via the Priya Life Science USA tracker

Sponsor

NuvOx LLC

Phase

Observational

Started

2025-12-08

Last updated

2026-02-18

Condition(s) studied

Glioblastoma (GBM)

Study summary

The goal of this sub-study of the RESTORE trial is to identify biomarkers associated with tumor hypoxia, identify biomarkers that differentiate pseudoprogression from true progression, and correlate biomarkers with clinical outcomes.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Subjects must be enrolled in the RESTORE study (NCT03862430) and provide written informed consent for the RESTORE LB sub-study

Primary outcome measure(s)

Tumor hypoxia biomarkers — until disease progression and up to 5 years
Identify differentially expressed tumor hypoxia markers in newly-diagnosed glioblastoma subjects treated with NanO2 versus placebo in the RESTORE study.

Trial sites (4)

Facility	City	Region
Center for Neurosciences	Tucson	Arizona
Yale Cancer Center	New Haven	Connecticut
Saint Luke's Cancer Institute	Kansas City	Missouri
Duke University Medical Center	Durham	North Carolina

More NuvOx LLC trials in the USA

A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM Active, not recruiting

Other trials for the same condition

Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer Starting soon

Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy Starting soon

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII Recruiting

A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients Recruiting

DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM) Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07417774 on ClinicalTrials.gov ↗ ← All trials in the USA